The Association for Molecular Pathology (AMP) has published a set of 13 best practice recommendations for validating and reporting clinical circulating tumor DNA (ctDNA) or liquid biopsy assays and ...

The last two decades have witnessed the steady growth of the protein drug market. As original recombinant products come off patent, generics/ biosimilars are also beginning to be manufactured. The ...

Independent clinical validation strengthens ABL’s leadership in the fast‑growing HIV drug‑resistance testing market ABL ...

A new wave of automated, inexpensive, and high-throughput multiplexing technologies has been widely reported on of late. Diagnostic laboratories and clinical pharmacologists will find these ...

Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non–Small-Cell Lung Cancer The two droplet digital polymerase chain reaction assays reported VAF values very close to the ...

A new chapter is unfolding for gene therapies in Europe. With retinal programs advancing into Phase I/II trials and ...

Cancer biomarkers span a broad biological spectrum, including proteins, metabolites, and nucleic acids detectable in samples such as tissue biopsies and blood. 1 At the beginning of a biomarker ...

Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform The Company had previously announced the commencement of commercial ...

Using a program that computes tumor decay (d) and regrowth (g) rates and the fraction (Φ) of tumor killed to assist in clinical trials and improve patient survival. Background: Currently there is no ...